These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7827172)

  • 1. Antiviral and anticancer ribozymes.
    Poeschla E; Wong-Staal F
    Curr Opin Oncol; 1994 Nov; 6(6):601-6. PubMed ID: 7827172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic applications of ribozymes.
    Kijima H; Ishida H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Pharmacol Ther; 1995; 68(2):247-67. PubMed ID: 8719970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic applications of catalytic antisense RNAs (ribozymes).
    Rossi JJ
    Ciba Found Symp; 1997; 209():195-204; discussion 204-6. PubMed ID: 9383577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Nucleic Acids Res; 1997 Aug; 25(15):3074-81. PubMed ID: 9224607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribozymes as antiviral agents.
    Bartolomé J; Castillo I; Carreño V
    Minerva Med; 2004 Feb; 95(1):11-24. PubMed ID: 15041923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribozymes in the age of molecular therapeutics.
    Bagheri S; Kashani-Sabet M
    Curr Mol Med; 2004 Aug; 4(5):489-506. PubMed ID: 15267221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozymes: killing the messenger.
    Barinaga M
    Science; 1993 Dec; 262(5139):1512-4. PubMed ID: 8248799
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M; Kuwabara T; Taira K
    Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of ribozymes.
    James HA; Gibson I
    Blood; 1998 Jan; 91(2):371-82. PubMed ID: 9427689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
    James H; Mills K; Gibson I
    Leukemia; 1996 Jun; 10(6):1054-64. PubMed ID: 8667643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV and Ribozymes.
    Scarborough RJ; Gatignol A
    Adv Exp Med Biol; 2015; 848():97-116. PubMed ID: 25757617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA enzymes (ribozymes) as antiviral therapeutic agents.
    Rossi JJ; Sarver N
    Trends Biotechnol; 1990 Jul; 8(7):179-83. PubMed ID: 1366622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses.
    Alvarez-Salas LM; Benítez-Hess ML; DiPaolo JA
    Antivir Ther; 2003 Aug; 8(4):265-78. PubMed ID: 14518695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of ribozymes to HIV infection.
    Rossi JJ
    Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential use of catalytic RNAs in therapy of HIV infection and other diseases.
    Rossi JJ; Cantin EM; Sarver N; Chang PF
    Pharmacol Ther; 1991; 50(2):245-54. PubMed ID: 1763136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection.
    Smythe JA; Symonds G
    Inflamm Res; 1995 Jan; 44(1):11-5. PubMed ID: 7664023
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
    Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
    Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.